EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia.
Leguay
T
T
Foucaud
C
C
Parrens
M
M
Fitoussi
O
O
Bouabdallah
K
K
Belaud-Rotureau
M A
MA
Tabrizi
R
R
Marit
G
G
Pigneux
A
A
Milpied
N
N
D000970:Antineoplastic Agents / Q000009:adverse effects; D001549:Benzamides; D049109:Cell Proliferation; D005260:Female; D004854:Herpesvirus 4, Human / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007679:Kidney Medulla / Q000821:virology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008099:Liver / Q000821:virology*; D008232:Lymphoproliferative Disorders / Q000139:chemically induced / Q000378:metabolism / Q000821:virology*; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D012008:Recurrence; D013154:Spleen / Q000821:virology*; D014178:Translocation, Genetic
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate